CLIN CANCER RES:利用PET检测CD8+T细胞密度

2018-10-29 MedSci MedSci原创

利用PET 对CD8 + T细胞进行无创和定量评估可以用于评估免疫治疗反应。CLIN CANCER RES近期发表了一篇文章,应用标记有64 Cu 的抗CD8 cys-双抗体来评估正常组织和并不组织的PET成像敏感性。

利用PET 对CD8 + T细胞进行无创和定量评估可以用于评估免疫治疗反应。CLIN CANCER RES近期发表了一篇文章,应用标记有64 Cu 的抗CD8 cys-双抗体来评估正常组织和并不组织的PET成像敏感性。

作者研发了具有64 Cu放射性标记的抗CD8 cys-双抗体(169cDb)。使用PET / CT评估静脉给药后64 Cu-169cDb 的积聚情况及其在野生型小鼠中的生物分布情况。通过免疫组化或流式细胞学研究CpG和αPD-1处理过的荷瘤小鼠中肿瘤浸润CD8 + T细胞情况。研究结果表明,结果:immunPET具有检测小鼠品系及淋巴组织(包括正常小鼠肠道)之间CD8 + T细胞微小分布差异的能力。在携带同源HER2驱动的乳腺癌(NDL)模型的FVB小鼠中,64 Cu-169cDb PET成像可以对免疫治疗的肿瘤浸润性CD8 + T细胞的变化准确地进行可视化及量化。

研究结果表明,64 Cu-169cDb成像在空间上可以反应正常器官和肿瘤中CD8 + T细胞的分布情况。临床前评估表明,可以通过ImmunoPET成像检测到免疫治疗引起的肿瘤浸润细胞毒性CD8 + T细胞密度的变化。

原始出处:

Jai Woong Seo, Richard Tavaré, et al. CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. CLIN CANCER RES. October 2018 doi: 10.1158/1078-0432.CCR-18-0261

本文系梅斯医学(MedSci)原创编译整理,转载需授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1727696, encodeId=094a1e27696e0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jan 29 23:35:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784055, encodeId=a4551e84055b2, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 07 06:35:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331113, encodeId=fe4e1331113d6, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Wed Oct 31 11:35:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605389, encodeId=b4241605389e5, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Oct 31 11:35:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350955, encodeId=471435095536, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Oct 30 13:03:44 CST 2018, time=2018-10-30, status=1, ipAttribution=)]
    2019-01-29 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1727696, encodeId=094a1e27696e0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jan 29 23:35:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784055, encodeId=a4551e84055b2, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 07 06:35:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331113, encodeId=fe4e1331113d6, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Wed Oct 31 11:35:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605389, encodeId=b4241605389e5, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Oct 31 11:35:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350955, encodeId=471435095536, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Oct 30 13:03:44 CST 2018, time=2018-10-30, status=1, ipAttribution=)]
    2019-08-07 gds2009
  3. [GetPortalCommentsPageByObjectIdResponse(id=1727696, encodeId=094a1e27696e0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jan 29 23:35:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784055, encodeId=a4551e84055b2, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 07 06:35:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331113, encodeId=fe4e1331113d6, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Wed Oct 31 11:35:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605389, encodeId=b4241605389e5, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Oct 31 11:35:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350955, encodeId=471435095536, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Oct 30 13:03:44 CST 2018, time=2018-10-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1727696, encodeId=094a1e27696e0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jan 29 23:35:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784055, encodeId=a4551e84055b2, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 07 06:35:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331113, encodeId=fe4e1331113d6, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Wed Oct 31 11:35:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605389, encodeId=b4241605389e5, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Oct 31 11:35:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350955, encodeId=471435095536, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Oct 30 13:03:44 CST 2018, time=2018-10-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1727696, encodeId=094a1e27696e0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jan 29 23:35:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784055, encodeId=a4551e84055b2, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Aug 07 06:35:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331113, encodeId=fe4e1331113d6, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Wed Oct 31 11:35:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605389, encodeId=b4241605389e5, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Oct 31 11:35:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350955, encodeId=471435095536, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Oct 30 13:03:44 CST 2018, time=2018-10-30, status=1, ipAttribution=)]
    2018-10-30 kafei

    学习了谢谢

    0

相关资讯

NEJM:三阴性乳腺癌免疫治疗的新希望

欧洲肿瘤内科学会(ESMO)2018年大会发布的IMpassion130研究显示,免疫疗法对三阴性乳腺癌有效,使用抗程序性细胞死亡配体1(PD-L1)药物Atezolizumab(商品名Tecentriq,基因泰克公司)联合化疗治疗PD-L1阳性(PD-L1+)三阴性乳腺癌患者,显示出生存益处。该研究同步发表在《新英格兰医学杂志》(NEJM)。

MAbs:广州生物院在肿瘤免疫治疗小鼠模型构建研究中获进展

该研究探索了利用患者外周血淋巴细胞快速建立小鼠模型的方法,并首次建立了免疫系统与肿瘤组织来源于同一患者的小鼠模型。

JAMA Oncology :免疫治疗相关致死性毒性的系统综述

免疫检查点抑制剂(ICI)改变了肿瘤治疗的临床实践,成为实体瘤的主流治疗手段之一。和单药免疫治疗相比,免疫联合治疗更是进一步提高了缓解率,改善了患者的临床结局。在治疗获益同时,免疫治疗相关毒性(irAE)也越来越得到关注,从2017年至今的一年多时间里,各个专业肿瘤学会分别出台了多个irAE的指南/共识,包括ESMO、SITC、ASCO/NCCN等,以指导临床医生处理irAE。

聚力免疫治疗:价格该如何定,有哪些政策加持……

近年来,免疫疗法已成为国内外肿瘤治疗研究领域的热点之一,在2013年《科学》杂志评出的年度十大科学突破排行榜中,免疫疗法高居榜首,其有望成为继手术、化疗、放疗、肿瘤靶向治疗后的新一代肿瘤治疗手段。

2018 ESMO:沈琳教授团队专访:突破神经内分泌肿瘤疗效瓶颈,免疫治疗任重而道远

近日,2018 ESMO大会在德国慕尼黑隆重召开。在本次ESMO大会上,由北京大学肿瘤医院沈琳教授牵头的JS001治疗晚期神经内分泌肿瘤的IB期研究的结果得以口头报告公布。JS001是我国君实生物自主研发具有全球知识产权的重组人源化PD-1单抗,前期临床研究表明JS001在多个瘤种中均具有一定疗效。特别采访到沈琳教授及其团队的李洁教授和张盼盼博士,共同解读与探讨这项研究的结果。

NEJM:免疫治疗在晚期三阴乳腺癌III期临床试验中成功!中位总生存期提高61.3%

《新英格兰医学杂志》便再次传来捷报。PD-L1抑制剂首次在晚期三阴乳腺癌临床Ⅲ期试验中取得重大胜利!该试验是由伦敦玛丽女王大学Peter Schmid教授领导的团队完成的。他们将免疫检查点抑制剂Atezolizumab与化疗药物白蛋白结合型紫杉醇(nab-paclitaxel)联用,与单独使用白蛋白结合型紫杉醇相比,PD-L1阳性的晚期三阴乳腺癌患者中位总生存期提升了近10个月,达到25个月,